Key Players
Competitive Landscape
Liquid biopsy competition follows the route from a collected sample to a result that can support a clinical decision, with companies supplying different parts of that route. Guardant Health develops blood-based oncology tests, including Shield’s specified screening use, while F. Hoffmann-La Roche Ltd. participates through molecular diagnostics. QIAGEN, Bio-Rad Laboratories and Thermo Fisher Scientific contribute sample, analytical or sequencing technologies used in laboratory testing. [2] These positions call for different purchasing comparisons: a clinical service needs evidence for its intended population and a reporting pathway, whereas laboratory buyers also assess the platform and sample requirements supporting their assay. The distinction places validated use and dependable delivery alongside analytical capability in competitive assessment. [1][3][4]
Market developments mapped to drivers, trends and opportunities (2026 to 2036)
Table 10: Market developments in Liquid Biopsy Market
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| FDA approved Shield in July 2024 for its specified colorectal-cancer screening population. [2] | A screening service needs evidence for the population and clinical purpose in which it will be used. | Blood-based testing is developing through defined indications. | Providers can organize access and follow-up around the authorized screening use. |
| NHS England announced a ctDNA rollout in May 2025 for eligible lung and breast cancer patients. [3] | Oncology teams need molecular information within the treatment-selection window. | Blood collection, laboratory analysis and reporting are becoming connected service requirements. | Testing services can improve the route from an eligible patient to an interpretable treatment-selection result. |
| ESMO's ctDNA recommendations connect assay use with the available clinical evidence. [4] | Different oncology decisions require evidence appropriate to the intended application. | Screening, treatment selection and monitoring remain separate assessment questions. | Assay providers can define a focused clinical proposition with clear reporting and follow-up arrangements. |
Source: US Food and Drug Administration; NHS England; European Society for Medical Oncology.
How do testing companies and laboratory suppliers compete in liquid biopsy?
A complete clinical test and a laboratory technology purchase occupy different positions between sample collection and the oncology decision. Guardant Health supplies blood-based testing, while F. Hoffmann-La Roche Ltd. participates in molecular diagnostics and QIAGEN, Bio-Rad Laboratories and Thermo Fisher Scientific supply technologies supporting molecular analysis. The clinical service needs an evidence-based intended use and a reporting route, whereas a laboratory selecting technology also needs to establish how that platform supports its particular assay. [1][4]
What do the documented clinical developments show about supplier capability?
Shield's July 2024 approval demonstrates a defined colorectal-cancer screening indication, while NHS England's ctDNA service addresses treatment selection for eligible lung and breast cancer patients. [2][3] These developments show why clinical purpose matters when comparing offerings: evidence supporting one decision does not establish every other use of liquid biopsy. A supplier's capability becomes useful through the patient population, sample and reporting process for which the test has been developed, with the interpretation connected to an appropriate next step. [4]
What should an oncology service evaluate before adopting a liquid biopsy offering?
The patient group and clinical question should establish the comparison, followed by the assay's evidence, sample requirements and laboratory turnaround. A result needs to arrive in time for the intended treatment discussion and provide information the team can interpret within that setting. [1][3] Low tumor-derived signal can also leave the question unresolved, making the route for further assessment relevant to the service arrangement alongside the analytical platform and the commercial terms of testing. [4]
Where could competitive opportunities develop through 2036?
Services that connect an appropriate patient with a timely molecular result can address a practical need in precision oncology, particularly when the finding informs an available treatment decision. [1][3] Competition can therefore develop around the collection and laboratory route as well as assay capability, with providers explaining what a result can resolve and the follow-up needed when it cannot. Clinical evidence for the intended use remains central as companies consider additional testing applications. [4]
Representative Company Overview
Table 11: Representative company overview for liquid biopsy market
| Company | Positioning | Recent development or documented offering |
|---|---|---|
| Guardant Health | Blood-based oncology testing | Shield's July 2024 FDA approval covers a specified colorectal-cancer screening population, giving purchasers a defined indication around which collection and follow-up services can be organized. [2] |
| F. Hoffmann-La Roche Ltd. | Molecular diagnostics | Its oncology molecular-testing participation places diagnostic information within the clinical pathway, where the intended assay and interpretation requirements determine the relevant laboratory offering. |
| QIAGEN | Molecular testing and sample technologies | Its sample and molecular-analysis technologies contribute to the preparation and testing route, making compatibility with the laboratory's intended assay an important procurement consideration. |
| Bio-Rad Laboratories | Molecular analysis systems | Its analytical platforms support liquid-biopsy research and testing activities, giving laboratories a technology choice whose suitability depends on the molecular measurement and workflow being established. |
| Thermo Fisher Scientific | Sequencing and molecular testing platforms | Its sequencing and laboratory technologies support oncology molecular analysis, with sample handling, assay requirements and the reporting process shaping how a laboratory uses the platform. |
Research Methodology
Liquid biopsy research distinguishes the biological target being measured from the sample collected and the clinical decision the result may support. FMI market coverage provides the segmentation and outlook, while NCI information frames biomarker testing within cancer treatment. [1] FDA's Shield decision is considered for its specified screening indication, and the NHS England rollout supplies a separate example of circulating tumor DNA used in treatment selection. [2][3] ESMO recommendations inform the interpretation of evidence for circulating tumor DNA applications. [4] Country and company assessments retain these differences in intended use, laboratory delivery and clinical interpretation, so a screening authorization or service introduction is not extended to unrelated cancers, biomarkers or testing purposes.
